Ali Norouzi also underlined the necessity to complete the construction of the isotope separation center, enhance cooperation with knowledge-based companies and universities across the country, and revive the National Fusion Center in Iran.
Norouzi stated in the past Iranian year (1403), the Advanced Technologies Company vigorously pursued its activities in two key areas—stable isotope production and nuclear fusion.
He said, “We successfully produced iridium hexafluoride feedstock, which is used to separate Iridium-191. When placed in a reactor, Iridium-191 transforms into Iridium-192, a radiopharmaceutical used to treat head, neck, and breast cancers.”
The CEO of Iran’s Advanced Technologies Company added: “In 1403, we also achieved the production of tellurium dioxide, which is used in the diagnosis and treatment of thyroid cancers. Additionally, we began manufacturing similar products, including Xenon-129, used in lung MRI imaging.”
He further noted: “Last year, we launched the second and final phase of constructing the National Research and Stable Isotope Production Center using gas centrifuge technology. This facility will encompass large-scale enrichment and isotope separation processes. Once completed, Iran will achieve full self-sufficiency in producing stable isotopes, which serve as raw materials for radiopharmaceuticals.”
Norouzi also highlighted the role of Iranian knowledge-based companies in advancing the country’s nuclear progress.
